HROW
Price
$38.82
Change
-$1.19 (-2.97%)
Updated
Aug 15 closing price
Capitalization
1.44B
92 days until earnings call
LFCR
Price
$7.37
Change
-$0.05 (-0.67%)
Updated
Aug 15 closing price
Capitalization
275.7M
46 days until earnings call
Interact to see
Advertisement

HROW vs LFCR

Header iconHROW vs LFCR Comparison
Open Charts HROW vs LFCRBanner chart's image
Harrow
Price$38.82
Change-$1.19 (-2.97%)
Volume$881.45K
Capitalization1.44B
Lifecore Biomedical
Price$7.37
Change-$0.05 (-0.67%)
Volume$70.88K
Capitalization275.7M
HROW vs LFCR Comparison Chart in %
Loading...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HROW vs. LFCR commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HROW is a Hold and LFCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (HROW: $38.82 vs. LFCR: $7.37)
Brand notoriety: HROW and LFCR are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HROW: 172% vs. LFCR: 42%
Market capitalization -- HROW: $1.44B vs. LFCR: $275.7M
HROW [@Pharmaceuticals: Generic] is valued at $1.44B. LFCR’s [@Pharmaceuticals: Generic] market capitalization is $275.7M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HROW’s FA Score shows that 1 FA rating(s) are green whileLFCR’s FA Score has 1 green FA rating(s).

  • HROW’s FA Score: 1 green, 4 red.
  • LFCR’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than LFCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HROW’s TA Score shows that 6 TA indicator(s) are bullish while LFCR’s TA Score has 5 bullish TA indicator(s).

  • HROW’s TA Score: 6 bullish, 4 bearish.
  • LFCR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, HROW is a better buy in the short-term than LFCR.

Price Growth

HROW (@Pharmaceuticals: Generic) experienced а +12.75% price change this week, while LFCR (@Pharmaceuticals: Generic) price change was +1.80% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

HROW is expected to report earnings on Nov 17, 2025.

LFCR is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HROW($1.44B) has a higher market cap than LFCR($276M). HROW YTD gains are higher at: 15.708 vs. LFCR (-0.808). HROW has higher annual earnings (EBITDA): 18.6M vs. LFCR (-13.57M). HROW has more cash in the bank: 66.7M vs. LFCR (5.42M). LFCR has less debt than HROW: LFCR (130M) vs HROW (230M). HROW has higher revenues than LFCR: HROW (213M) vs LFCR (130M).
HROWLFCRHROW / LFCR
Capitalization1.44B276M520%
EBITDA18.6M-13.57M-137%
Gain YTD15.708-0.808-1,945%
P/E RatioN/A51.23-
Revenue213M130M164%
Total Cash66.7M5.42M1,231%
Total Debt230M130M177%
FUNDAMENTALS RATINGS
HROW vs LFCR: Fundamental Ratings
HROW
LFCR
OUTLOOK RATING
1..100
1760
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
46100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4049
P/E GROWTH RATING
1..100
116
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HROW's Valuation (84) in the Pharmaceuticals Other industry is in the same range as LFCR (99) in the Industrial Specialties industry. This means that HROW’s stock grew similarly to LFCR’s over the last 12 months.

HROW's Profit vs Risk Rating (46) in the Pharmaceuticals Other industry is somewhat better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that HROW’s stock grew somewhat faster than LFCR’s over the last 12 months.

HROW's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as LFCR (100) in the Industrial Specialties industry. This means that HROW’s stock grew similarly to LFCR’s over the last 12 months.

HROW's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as LFCR (49) in the Industrial Specialties industry. This means that HROW’s stock grew similarly to LFCR’s over the last 12 months.

LFCR's P/E Growth Rating (6) in the Industrial Specialties industry is in the same range as HROW (11) in the Pharmaceuticals Other industry. This means that LFCR’s stock grew similarly to HROW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HROWLFCR
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
72%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
73%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 17 days ago
81%
Bearish Trend 3 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 4 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ICERX46.080.43
+0.94%
NYLI Epoch International Chc SIMPLE Cl
MWEBX41.240.13
+0.32%
MFS Global Equity B
CHCGX58.43-0.13
-0.22%
Chesapeake Growth
PGBGX50.47-0.14
-0.28%
Principal Blue Chip R5
HWVIX12.12-0.13
-1.06%
Hotchkis & Wiley Sm Cp Divers Val I

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AQST. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AQST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
-2.97%
AQST - HROW
35%
Loosely correlated
N/A
OGI - HROW
34%
Loosely correlated
-8.33%
AMRX - HROW
32%
Poorly correlated
+0.64%
VTRS - HROW
32%
Poorly correlated
-0.75%
NBIX - HROW
30%
Poorly correlated
+1.21%
More

LFCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LFCR has been loosely correlated with NBIX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if LFCR jumps, then NBIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
-0.67%
NBIX - LFCR
35%
Loosely correlated
+1.21%
SHPH - LFCR
31%
Poorly correlated
-5.14%
ALKS - LFCR
25%
Poorly correlated
+2.80%
HROW - LFCR
25%
Poorly correlated
-2.97%
AMRX - LFCR
25%
Poorly correlated
+0.64%
More